Clinical Trial Update: Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating AFQ056 for reducing cocaine use in cocaine use disorder has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cocaine-related Disorder

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cocaine-related Disorder | Phase 2 | Status: COMPLETED | Results posted: 2021-02-04